Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers-Early Experiences from Romania and Literature Review.
Camil Ciprian MireșteanMihai Cosmin StanMichael SchenkerConstantin VolovațSimona Ruxandra VolovățDragoș Teodor Petru IancuRoxana Irina IancuFlorinel BădulescuPublished in: Diagnostics (Basel, Switzerland) (2023)
Prognosis in recurrent/metastatic head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is poor, making therapy optimization a priority. Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody Nivolumab was approved in such cases. We present the early experience with Nivolumab immunotherapy at three cancer clinics from south and northeast Romania, aiming to describe the main characteristics and outcomes relative to literature reports, and to suggest patient selection criteria. Diagnostic, clinical, biological, therapeutic, and outcomes-related data from January 2020 until March 2023 were analyzed retrospectively. Eighteen patients with platinum refractory HNSCC (85.7% men, median age 58.9) were administered Nivolumab for 1-14 months (median 5.6 months) in addition to other treatments (surgery, radiotherapy, chemotherapy), and monitored for up to 25 months. Median neutrophil-to-lymphocyte ratio (NLR) ranged from 2.72 initially to 6.01 during treatment. Overall survival (OS) was 16 months, and patients who died early had the sharpest NLR increases (13.07/month). There were no severe immune-related adverse events. Lower NLR values and combined intensive chemotherapy, radiotherapy, and immunotherapy were related to better outcomes. To our knowledge, we also report the first two cases of second primary malignancy (SPM) in the head and neck region treated with Nivolumab in Romania (for which the sequential administration of radiotherapy and immunotherapy seems better). The work of other Romanian authors on the role of HPV status in HNC is also discussed. Multi-center trials are needed in order to investigate and confirm these observations.
Keyphrases
- locally advanced
- squamous cell carcinoma
- early stage
- monoclonal antibody
- rectal cancer
- radiation therapy
- small cell lung cancer
- case report
- systematic review
- radiation induced
- minimally invasive
- mental health
- machine learning
- type diabetes
- stem cells
- papillary thyroid
- metabolic syndrome
- adverse drug
- glycemic control
- coronary artery bypass
- newly diagnosed
- lymph node metastasis
- chemotherapy induced
- weight loss